Insider Buying: Urogen Pharma Ltd (URGN) Insider Buys 272 Shares of Stock

Urogen Pharma Ltd (NASDAQ:URGN) insider Mark Schoenberg acquired 272 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The stock was acquired at an average price of $37.01 per share, for a total transaction of $10,066.72. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mark Schoenberg also recently made the following trade(s):

  • On Wednesday, March 6th, Mark Schoenberg sold 1,991 shares of Urogen Pharma stock. The shares were sold at an average price of $37.30, for a total value of $74,264.30.

Shares of NASDAQ URGN traded down $0.22 during mid-day trading on Monday, hitting $38.33. The company had a trading volume of 56,200 shares, compared to its average volume of 203,376. The stock has a market cap of $525.25 million, a P/E ratio of -8.00 and a beta of 1.44. Urogen Pharma Ltd has a 1-year low of $34.61 and a 1-year high of $69.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, February 28th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by ($0.17). Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 70.67%. As a group, sell-side analysts expect that Urogen Pharma Ltd will post -5.47 earnings per share for the current fiscal year.

URGN has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Urogen Pharma in a research note on Friday, March 1st. Oppenheimer set a $70.00 price target on Urogen Pharma and gave the stock a “buy” rating in a research note on Thursday, February 28th. Stifel Nicolaus restated a “buy” rating and set a $63.00 price target on shares of Urogen Pharma in a research note on Tuesday, March 5th. Finally, Raymond James set a $57.00 price target on Urogen Pharma and gave the stock a “buy” rating in a research note on Friday, March 1st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $68.40.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Tibra Equities Europe Ltd acquired a new stake in shares of Urogen Pharma in the first quarter valued at $1,259,000. Barclays PLC increased its holdings in Urogen Pharma by 6.4% in the fourth quarter. Barclays PLC now owns 21,281 shares of the company’s stock valued at $916,000 after buying an additional 1,281 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in Urogen Pharma by 28.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 399,262 shares of the company’s stock valued at $17,192,000 after buying an additional 89,262 shares during the last quarter. Delek Group Ltd. increased its holdings in Urogen Pharma by 64.1% in the fourth quarter. Delek Group Ltd. now owns 163,435 shares of the company’s stock valued at $7,226,000 after buying an additional 63,815 shares during the last quarter. Finally, United Services Automobile Association increased its holdings in Urogen Pharma by 4.5% in the fourth quarter. United Services Automobile Association now owns 31,950 shares of the company’s stock valued at $1,376,000 after buying an additional 1,387 shares during the last quarter. Institutional investors and hedge funds own 69.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/15/mark-schoenberg-purchases-272-shares-of-urogen-pharma-ltd-urgn-stock.html.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

See Also: The role of implied volatility with call option volume

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.